Drug
Microplasmin clinical trials
Also written Microplasmin, Ocriplasmin and JETREA™®.
- studies test it
- 22
- open now
- 0
- in phase 3
- 4
- first study started
- 2004
How studies write it
Studies that test it under each name
Studies by the year they started
22 studies that test it; most in 2010 (4)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 3 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 4 |
| 2011 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 15
- Phase 3
- 4
- Phase 4
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 19 · Other 3
ThromboGenics (16) · Alcon Research (3) · Universitaire Ziekenhuizen KU Leuven (1) · National Institutes of Health Clinical Center (CC) (1) · University of California, Los Angeles (1)
Studies
Open first, then newest update. How each study uses microplasmin is read from its arms, and is right about nine times in ten.
Testing it · 22
- A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDRTerminatedPhase 2ThromboGenicsNCT02681809Written as ocriplasmin 0.0625mg
- Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular AdhesionCompletedPhase 4Alcon ResearchNCT02322229Written as Ocriplasmin 0.125 mg in a 0.1 mL volume
- Microplasmin Intravitreal Administration in Participants With Uveitic Macular EdemaTerminatedPhase 1/2National Institutes of Health Clinical Center (CC)NCT01194674Written as Microplasmin
- Phase I RVC With Ocriplasmin for CRVOCompletedPhase 1Universitaire Ziekenhuizen KU LeuvenNCT02747030Written as Ocriplasmin intravenously
- Assessment of Patients Treated With JETREA® for Vitreomacular TractionCompletedPhase 4Alcon ResearchNCT02035748Written as Ocriplasmin
- Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular HoleCompletedPhase 3ThromboGenicsNCT01429441Written as Ocriplasmin
- A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular AdhesionCompletedPhase 3Alcon ResearchNCT01889251Written as Ocriplasmin
- Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular AdhesionCompletedPhase 2ThromboGenicsNCT00913744Written as Ocriplasmin
- Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for VitrectomyCompletedPhase 2ThromboGenicsNCT00986362Written as Ocriplasmin
- The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV)CompletedPhase 2ThromboGenicsNCT01159665Written as ocriplasmin
- A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)CompletedPhase 2ThromboGenicsNCT00412958Written as Ocriplasmin 25µg
- Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.CompletedPhase 3ThromboGenicsNCT00798317Written as Ocriplasmin 125µg
- A Study to Compare Multiple Doses Intravitreal Microplasmin for Treatment of Patients With Vitreomacular Traction (MIVI-IIt)CompletedPhase 2ThromboGenicsNCT00435539Written as ocriplasmin
- Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.CompletedPhase 3ThromboGenicsNCT00781859Written as 125 µg Ocriplasmin
- A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME)CompletedPhase 2ThromboGenicsNCT00412451Written as ocriplasmin
- Intravenous Administration of Microplasmin for Treatment of Acute Ischemic StrokeCompletedPhase 2ThromboGenicsNCT00123305Written as Microplasmin
- Safety and Efficacy Study of Microplasmin in for Non-Surgical Treatment of Focal Vitreomacular AdhesionCompletedPhase 2ThromboGenicsNCT01055535Written as Microplasmin
- Intravitreal Microplasmin in Patients Undergoing Surgical VitrectomyCompletedPhase 2ThromboGenicsNCT00123279Written as Microplasmin
- Microplasmin Administered Via the Trellis-8 Infusion System for Treatment of Acute Iliofemoral DVTTerminatedPhase 2ThromboGenicsNCT00428129Written as microplasmin
- Intra-arterial Microplasmin Administration in Patients With Acute Intracranial Vertebrobasilar Artery OcclusionTerminatedPhase 2ThromboGenicsNCT00123266Written as Microplasmin
Codes
What other systems call microplasmin · ClinicalTrials.gg INT003361
- MeSH (NLM) C054561microplasminOne source NLM
- UNII (FDA) 7V6HE3DM5AOCRIPLASMINConfirmed FDA, NLM
- RxNorm 29998One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C054561 | microplasmin | One source NLM |
| UNII (FDA) | 7V6HE3DM5A | OCRIPLASMIN | Confirmed FDA, NLM |
| RxNorm | 29998 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.